- Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study2023 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- Immuno-oncological treatment of melanoma2014 | Publication without faculty affiliation
- Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology2020 | Second Faculty of Medicine
- Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)2023 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Current procedures and news in the treatment of lung cancer2021 | First Faculty of Medicine
- Intra-Tumour Heterogeneity Is One of the Main Sources of Inter-Observer Variation in Scoring Stromal Tumour Infiltrating Lymphocytes in Triple Negative Breast Cancer2021 | Faculty of Medicine in Hradec Králové
- More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments2017 | Publication without faculty affiliation
- Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial2021 | First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Pilsen
- ONEST (Observers Needed to Evaluate Subjective Tests) Analysis of Stromal Tumour-Infiltrating Lymphocytes (sTILs) in Breast Cancer and Its Limitations2023 | Faculty of Medicine in Hradec Králové
- Renal Toxicity of Cancer Immunotherapy2020 | First Faculty of Medicine
- Comparison of RECIST 1.1 and iRECIST for response evaluation in solid tumours2017 | First Faculty of Medicine, Third Faculty of Medicine
- Comparison of five different scoring methods in the evaluation of inflammatory infiltration (tumor-infiltrating lymphocytes) in superficial spreading and nodular melanoma2019 | First Faculty of Medicine
- Immunotherapy of renal cell carcinoma2018 | First Faculty of Medicine
- CD19 expression in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia pre- and post-treatment with blinatumomab2021 | Second Faculty of Medicine
- Tumor mutation burden - a clinical oncologist's perspective2019 | First Faculty of Medicine
- Neurological complications of cancer immunotherapy2023 | Third Faculty of Medicine
- Trial watch: Dendritic cell (DC)-based immunotherapy for cancer2022 | Second Faculty of Medicine
- Treatment of non-small cell lung cancer with a driver mutation2022 | Faculty of Medicine in Pilsen
- News in the treatment of small cell lung cancer2022 | Faculty of Medicine in Pilsen
- Trial watch: chemotherapy-induced immunogenic cell death in oncology2023 | Second Faculty of Medicine
- New treatment options of transitional cell carcinoma of the urinary bladder in the era of immunotherapy2021 | Third Faculty of Medicine
- Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations2023 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies2022 | First Faculty of Medicine